MARKET

AMGN

AMGN

Amgen Inc
NASDAQ
379.73
+6.37
+1.71%
After Hours: 379.00 -0.73 -0.19% 19:56 02/18 EST
OPEN
373.50
PREV CLOSE
373.36
HIGH
380.58
LOW
370.44
VOLUME
2.73M
TURNOVER
--
52 WEEK HIGH
382.47
52 WEEK LOW
253.48
MARKET CAP
204.48B
P/E (TTM)
26.69
1D
5D
1M
3M
1Y
5Y
1D
NIH director reportedly being tapped as acting CDC director
Seeking Alpha · 11h ago
IXJ: Healthcare Sector Dashboard For February
Seeking Alpha · 15h ago
Dividend picks: 20 large-cap defensive stocks outperforming the market in 2026
Seeking Alpha · 16h ago
Amgen Is Maintained at Overweight by Piper Sandler
Dow Jones · 18h ago
Amgen price target raised to $432 from $381 at Piper Sandler
TipRanks · 18h ago
AMGEN INC FILES FOR FOUR-PART SENIOR NOTES OFFERING OF UP TO $4 BLN- SEC FILING
Reuters · 1d ago
Notable ETF Inflow Detected - DIA, GS, MSFT, AMGN
NASDAQ · 1d ago
AMGEN INC FILES FOR FOUR PART NOTES OFFERING; SIZE NOT DISCLOSED - SEC FILING
Reuters · 1d ago
More
About AMGN
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.

Webull offers Amgen Inc stock information, including NASDAQ: AMGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AMGN stock methods without spending real money on the virtual paper trading platform.